Concert Pharmaceuticals, Inc. CNCE announced that it has initiated a multiple-ascending dose (“MAD”) phase I study on its pipeline candidate, CTP-692 (a novel deuterium-modified form of D-serine), as an adjunctive treatment for schizophrenia.
The phase I program now includes three clinical studies, which will evaluate a single dose of CTP-692, multiple ascending dose of the candidate and compare the candidate with D-serine. Top-line data from the single-dose and MAD studies is expected in the second quarter of 2019.
The early-stage development program will evaluate the safety, tolerability and pharmacokinetics of CTP-692 in healthy volunteers. Data from the studies will support the progress of the candidate to advanced stages of development, which will evaluate the efficacy of CTP-652 as adjunct to standard antipsychotic medicines in improving positive and negative symptoms as well as cognitive function in schizophrenia patients.
The company believes that CTP-692 holds potential to offer a new approach of treating symptoms of schizophrenia. However, we note that development of candidates by multiple pharma companies related to brain disorders like Alzheimer’s and schizophrenia have faced setbacks in the past with several companies discontinuing development. Thus, development of CTP-692 may face a difficult path ahead.
Concert Pharmaceuticals is a small biotech developing candidates targeting multiple indications in central nervous system disorders, autoimmune disease and inflammation.